151 related articles for article (PubMed ID: 15692845)
1. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice.
Johnston D; Bystryn JC
Cancer Immunol Immunother; 2005 Apr; 54(4):345-50. PubMed ID: 15692845
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
3. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
4. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.
Applebaum J; Reynolds S; Knispel J; Oratz R; Shapiro R; Bystryn JC
J Natl Cancer Inst; 1998 Jan; 90(2):146-9. PubMed ID: 9450575
[TBL] [Abstract][Full Text] [Related]
5. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
6. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization.
Hafner C; Wagner S; Jasinska J; Allwardt D; Scheiner O; Wolff K; Pehamberger H; Wiedermann U; Breiteneder H
J Invest Dermatol; 2005 Jan; 124(1):125-31. PubMed ID: 15654965
[TBL] [Abstract][Full Text] [Related]
7. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
8. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
9. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
10. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
Hoon DS; Yuzuki D; Hayashida M; Morton DL
J Immunol; 1995 Jan; 154(2):730-7. PubMed ID: 7814879
[TBL] [Abstract][Full Text] [Related]
11. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
Riemer AB; Hantusch B; Sponer B; Kraml G; Hafner C; Zielinski CC; Scheiner O; Pehamberger H; Jensen-Jarolim E
Cancer Immunol Immunother; 2005 Jul; 54(7):677-84. PubMed ID: 15565329
[TBL] [Abstract][Full Text] [Related]
12. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine.
Miller K; Abeles G; Oratz R; Zeleniuch-Jacquotte A; Cui J; Roses DF; Harris MN; Bystryn JC
Cancer; 1995 Jan; 75(2):495-502. PubMed ID: 7812920
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.
Takahashi T; Conforti A; Kikumoto Y; Hoon DS; Morton DL; Irie RF
J Clin Immunol; 1998 Jul; 18(4):299-305. PubMed ID: 9710747
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of a polyvalent melanoma antigen vaccine.
Bystryn JC
Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
[TBL] [Abstract][Full Text] [Related]
16. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.
Ehlken H; Schadendorf D; Eichmüller S
Int J Cancer; 2004 Jan; 108(2):307-13. PubMed ID: 14639620
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity.
Hafner C; Wagner S; Allwardt D; Riemer AB; Scheiner O; Pehamberger H; Breiteneder H
Melanoma Res; 2005 Apr; 15(2):111-7. PubMed ID: 15846144
[TBL] [Abstract][Full Text] [Related]
20. Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg.
Chen Q; Li W; Wang P; Shao H; Ding Y; Wang W; Cen D; Cai Y; Xue X; Zhang L; Zhu G
Protein Pept Lett; 2017; 24(10):947-954. PubMed ID: 28641561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
